Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
09 mai 2024 09h00 HE
|
Curia Global, Inc.
The symposium, Unlocking High-Throughput Biology in Drug Discovery, will take place on May 31 in Seattle and feature industry-leading scientists.
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
09 mai 2024 07h15 HE
|
ADC Therapeutics SA
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024...
[Latest] Global Ultrapure Water Market Size/Share Worth USD 3,989 Million by 2033 at a 10.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
02 mai 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultrapure Water Market Size, Trends and Insights By Application (Cleaning,...
With Support from AWS, Yseop Develops a Unique Generative AI Application for Regulatory Document Generation Across BioPharma
02 mai 2024 09h00 HE
|
Yseop
Yseop, with support from Amazon Web Services (AWS), announced the development of an enhanced Generative AI application for the Biopharma industry.
New YPrime Report Highlights eCOA's Impact on CNS Trials
01 mai 2024 08h00 HE
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
30 avr. 2024 07h00 HE
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 avr. 2024 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two...
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
18 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
15 avr. 2024 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05 avr. 2024 16h05 HE
|
23andMe, Inc.
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...